[go: up one dir, main page]

DE602005006757D1 - Als muscarinrezeptorantagonisten geeignete biphenylverbindungen - Google Patents

Als muscarinrezeptorantagonisten geeignete biphenylverbindungen

Info

Publication number
DE602005006757D1
DE602005006757D1 DE602005006757T DE602005006757T DE602005006757D1 DE 602005006757 D1 DE602005006757 D1 DE 602005006757D1 DE 602005006757 T DE602005006757 T DE 602005006757T DE 602005006757 T DE602005006757 T DE 602005006757T DE 602005006757 D1 DE602005006757 D1 DE 602005006757D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
compounds suitable
biphenyl compounds
muscarin receptor
muscarin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005006757T
Other languages
English (en)
Inventor
Mathai Mammen
Yu-Hua Ji
Yongqi Mu
Craig Husfeld
Li Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of DE602005006757D1 publication Critical patent/DE602005006757D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005006757T 2004-03-11 2005-03-10 Als muscarinrezeptorantagonisten geeignete biphenylverbindungen Expired - Lifetime DE602005006757D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55244304P 2004-03-11 2004-03-11
PCT/US2005/007988 WO2005087738A1 (en) 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
DE602005006757D1 true DE602005006757D1 (de) 2008-06-26

Family

ID=34963910

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602005006757T Expired - Lifetime DE602005006757D1 (de) 2004-03-11 2005-03-10 Als muscarinrezeptorantagonisten geeignete biphenylverbindungen
DE602005021258T Expired - Lifetime DE602005021258D1 (de) 2004-03-11 2005-03-10 Biphenylverbindungen geeignet für die Synthese von Muscarinrezeptorantagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602005021258T Expired - Lifetime DE602005021258D1 (de) 2004-03-11 2005-03-10 Biphenylverbindungen geeignet für die Synthese von Muscarinrezeptorantagonisten

Country Status (27)

Country Link
US (22) US7288657B2 (de)
EP (2) EP1930323B1 (de)
JP (1) JP4837653B2 (de)
KR (1) KR101174740B1 (de)
CN (1) CN1930125B (de)
AR (2) AR048032A1 (de)
AT (2) ATE467617T1 (de)
AU (1) AU2005222411B2 (de)
BR (1) BRPI0508622B8 (de)
CA (1) CA2557479C (de)
CY (1) CY1109015T1 (de)
DE (2) DE602005006757D1 (de)
DK (1) DK1723114T3 (de)
ES (2) ES2306125T3 (de)
HR (1) HRP20080301T3 (de)
IL (1) IL177359A (de)
MA (1) MA28524B1 (de)
MY (1) MY144482A (de)
NO (1) NO338941B1 (de)
NZ (1) NZ549472A (de)
PL (1) PL1723114T3 (de)
PT (1) PT1723114E (de)
RU (1) RU2366656C2 (de)
SI (1) SI1723114T1 (de)
TW (1) TWI341836B (de)
WO (1) WO2005087738A1 (de)
ZA (1) ZA200607099B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723112A1 (de) * 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten für den muscarinrezeptor geeignete biphenylverbindungen
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (de) * 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528416A (ja) * 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528412A (ja) * 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス, インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008533028A (ja) * 2005-03-10 2008-08-21 セラヴァンス, インコーポレーテッド ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物
EP1866284A1 (de) * 2005-03-10 2007-12-19 Theravance, Inc. Biphenylverbindungen als muskarinrezeptorantagonisten
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7728144B2 (en) 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
PL2599778T3 (pl) 2009-04-23 2018-01-31 Theravance Respiratory Co Llc Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
BR112012000890A2 (pt) 2009-07-15 2017-10-31 Theravance Inc formas de base livre cristalina de um composto bifenil
JP5959117B2 (ja) 2010-07-13 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ビフェニル−2−イルカルバミン酸を調製するためのプロセス
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9679336B2 (en) * 2011-10-19 2017-06-13 Facebook, Inc. Social ad hoc networking protocol and presentation layer
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
WO2017054702A1 (zh) * 2015-09-28 2017-04-06 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
WO2017063564A1 (zh) * 2015-10-13 2017-04-20 四川海思科制药有限公司 一种八氢环戊二烯并[c]吡咯衍生物及其制备方法和在医药上的用途
WO2020047225A1 (en) 2018-08-30 2020-03-05 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US11591323B2 (en) * 2019-03-06 2023-02-28 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
CN110526859B (zh) * 2019-08-07 2021-03-12 山东百诺医药股份有限公司 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023017404A1 (en) * 2021-08-13 2023-02-16 Begum Dr M Sasthaa A device, a compound, for inhalation of an anti-viral agent
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN116496206A (zh) * 2023-04-21 2023-07-28 斯坦德药典标准物质研发(湖北)有限公司 一种雷芬那辛杂质ii及其制备方法
CN116640088A (zh) * 2023-05-29 2023-08-25 新领先(重庆)医药科技有限公司 一种高纯度雷芬那辛的制备方法
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US747952A (en) * 1903-03-02 1903-12-29 Harry Cauley Dillon Ironing-board.
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
SE8603252L (sv) 1985-07-30 1987-01-31 Glaxo Group Ltd Anordning for att tillfora lekemedel till patienter
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
PT613371E (pt) 1991-12-18 2002-07-31 Astrazeneca Ab Nova combinacao de formoterol e budesonido
ATE204743T1 (de) 1991-12-18 2001-09-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
GB9206989D0 (en) 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
EP0747355A4 (de) 1994-02-10 1997-04-09 Yamanouchi Pharma Co Ltd Neue carbamate und diese enthaltende arzneimittel
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
RO119116B1 (ro) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. Inhalator pentru dozarea salmeterolului
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンpdeiii/iv阻害剤
AU755066B2 (en) 1998-04-18 2002-12-05 Glaxo Group Limited Pharmaceutical aerosol formulation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
WO1999064043A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Muscarinic receptor antagonists
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PT1169019E (pt) 1999-04-14 2003-07-31 Glaxo Group Ltd Formulacao farmaceutica em aerossol
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6510182B1 (en) * 1999-10-25 2003-01-21 Freesystems Pte. Ltd. Wireless infrared digital audio system
EP1235802B1 (de) 1999-12-07 2005-07-13 Theravance, Inc. Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
ATE305468T1 (de) 2000-12-22 2005-10-15 Almirall Prodesfarma Ag Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ グループ リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
AU2003258507A1 (en) 2002-07-30 2004-02-23 Unilever Plc Abrasive hard surface cleaning compositions
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4851937B2 (ja) * 2003-11-21 2012-01-11 セラヴァンス, インコーポレーテッド β2アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723112A1 (de) 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten für den muscarinrezeptor geeignete biphenylverbindungen
EP1723113A1 (de) * 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528416A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2007528412A (ja) * 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとして有用なビフェニル化合物
EP1723109A1 (de) 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
JP2008537931A (ja) 2005-03-10 2008-10-02 セラヴァンス, インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1866284A1 (de) 2005-03-10 2007-12-19 Theravance, Inc. Biphenylverbindungen als muskarinrezeptorantagonisten
JP2008533028A (ja) 2005-03-10 2008-08-21 セラヴァンス, インコーポレーテッド ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7728144B2 (en) 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
US20070029346A1 (en) * 2005-08-03 2007-02-08 Fu-Tian Hung Pneumatic greaser
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2009535462A (ja) * 2006-04-27 2009-10-01 インテザイン テクノロジーズ, インコーポレイテッド 化学的に異なる末端基を含むポリ(エチレングリコール)
BR112012000890A2 (pt) 2009-07-15 2017-10-31 Theravance Inc formas de base livre cristalina de um composto bifenil
JP5959117B2 (ja) 2010-07-13 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ビフェニル−2−イルカルバミン酸を調製するためのプロセス

Also Published As

Publication number Publication date
EP1930323B1 (de) 2010-05-12
MY144482A (en) 2011-09-30
US20090226379A1 (en) 2009-09-10
RU2006135927A (ru) 2008-04-20
CA2557479C (en) 2013-05-07
PT1723114E (pt) 2008-07-17
US8173815B2 (en) 2012-05-08
IL177359A (en) 2012-04-30
EP1930323A1 (de) 2008-06-11
US20070292357A1 (en) 2007-12-20
US10570092B2 (en) 2020-02-25
BRPI0508622B8 (pt) 2021-05-25
US8053448B2 (en) 2011-11-08
US8557997B2 (en) 2013-10-15
US8912334B2 (en) 2014-12-16
DK1723114T3 (da) 2008-07-28
SI1723114T1 (sl) 2008-08-31
ATE467617T1 (de) 2010-05-15
US12258316B2 (en) 2025-03-25
US20110130422A1 (en) 2011-06-02
AU2005222411B2 (en) 2011-04-21
JP2008532922A (ja) 2008-08-21
US20190047957A1 (en) 2019-02-14
CA2557479A1 (en) 2005-09-22
ATE395335T1 (de) 2008-05-15
NO338941B1 (no) 2016-10-31
AU2005222411A1 (en) 2005-09-22
US20100249421A1 (en) 2010-09-30
DE602005021258D1 (de) 2010-06-24
NO20064579L (no) 2006-11-08
CN1930125A (zh) 2007-03-14
EP1723114B1 (de) 2008-05-14
US7585879B2 (en) 2009-09-08
US8273894B2 (en) 2012-09-25
BRPI0508622B1 (pt) 2018-05-22
US20180179161A1 (en) 2018-06-28
US20090018165A1 (en) 2009-01-15
US7910608B2 (en) 2011-03-22
HK1119672A1 (en) 2009-03-13
US20070292356A1 (en) 2007-12-20
ES2345640T3 (es) 2010-09-28
US20130172301A1 (en) 2013-07-04
TWI341836B (en) 2011-05-11
US20190359570A1 (en) 2019-11-28
MA28524B1 (fr) 2007-04-03
EP1723114A1 (de) 2006-11-22
US20160220551A1 (en) 2016-08-04
JP4837653B2 (ja) 2011-12-14
US20200290966A1 (en) 2020-09-17
US20080095708A1 (en) 2008-04-24
KR101174740B1 (ko) 2012-08-17
US20110319625A1 (en) 2011-12-29
US20220306579A1 (en) 2022-09-29
US10106503B2 (en) 2018-10-23
WO2005087738A1 (en) 2005-09-22
PL1723114T3 (pl) 2008-10-31
RU2366656C2 (ru) 2009-09-10
US8034946B2 (en) 2011-10-11
US20050203133A1 (en) 2005-09-15
US20170204061A1 (en) 2017-07-20
HK1097537A1 (en) 2007-06-29
ES2306125T3 (es) 2008-11-01
CY1109015T1 (el) 2014-07-02
US20120190657A1 (en) 2012-07-26
AR048032A1 (es) 2006-03-22
NZ549472A (en) 2010-06-25
US20070265305A1 (en) 2007-11-15
KR20070011370A (ko) 2007-01-24
US20140171397A1 (en) 2014-06-19
US10343995B2 (en) 2019-07-09
BRPI0508622A (pt) 2007-07-31
US8017783B2 (en) 2011-09-13
TW200538438A (en) 2005-12-01
CN1930125B (zh) 2010-07-21
US20150164795A1 (en) 2015-06-18
US20080071088A1 (en) 2008-03-20
HRP20080301T3 (en) 2008-09-30
US9926272B2 (en) 2018-03-27
US9283183B2 (en) 2016-03-15
US9452161B2 (en) 2016-09-27
US7803812B2 (en) 2010-09-28
US7491736B2 (en) 2009-02-17
US7288657B2 (en) 2007-10-30
AR104444A2 (es) 2017-07-19
US7550595B2 (en) 2009-06-23
IL177359A0 (en) 2006-12-10
ZA200607099B (en) 2008-09-25
US7521041B2 (en) 2009-04-21
US11247969B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
ATE395335T1 (de) Als muscarinrezeptorantagonisten geeignete biphenylverbindungen
CY2017008I2 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
DK1740177T3 (da) Antagonister til muskarinfølsomme acetylcholinreceptorer
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
ATE413400T1 (de) Cgrp-rezeptorantagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK2009992T3 (da) Il-8 receptor-antagonister
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
ATE545633T1 (de) Als vasopressinantagonisten geeignete benzazepinderivate
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
ATE517100T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE519738T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
EP1799672A4 (de) Cgrp-rezeptorantagonisten
EP1812008A4 (de) Il-8-rezeptorantagonisten
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602006018334D1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
ATE528291T1 (de) Cyclopropylderivate als nk3 rezeptor-antagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition